Evidence map›Paper›PMID 32910536›Full record

ReviewThe FEBS journal2021

Exosomes as mediators of immune regulation and immunotherapy in cancer.

Fernanda G Kugeratski, Raghu Kalluri

Abstract readReview
In one paragraph

Review in The FEBS journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Research on exosomes in cancer multidrug resistance and clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025
    Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fernanda G KugeratskiDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9731-1275
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2190-547X

Funding

Rigorous and reproducible mutational analysis of the urinary exosomal DNAR01CA231465 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., KALLURI, RAGHU · 2019 to 2023
$3.1M
Exosomes in Cancer TherapyR01CA213233 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2017 to 2021
$2.0M
Employing mouse models to translate early detection of pancreas cancerR01CA195733 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU, PIWNICA-WORMS, DAVID · 2015 to 2017
$1.6M
NCI NIH HHS R01 CA195733NCI NIH HHS R01 CA213233NCI NIH HHS R01 CA231465
6 · The paper itself

Abstract

Exosomes are nanosized extracellular vesicles of endosomal origin that enclose a multitude of functional biomolecules. Exosomes have emerged as key players of intercellular communication in physiological and pathological conditions. In cancer, depending on the context, exosomes can oppose or potentiate the development of an aggressive tumor microenvironment, thereby impacting tumor progression and clinical outcome. Increasing evidence has established exosomes as important mediators of immune regulation in cancer, as they deliver a plethora of signals that can either support or restrain immunosuppression of lymphoid and myeloid cell populations in tumors. Here, we review the current knowledge related to exosome-mediated regulation of lymphoid (T lymphocytes, B lymphocytes, and NK cells) and myeloid (macrophages, dendritic cells, monocytes, myeloid-derived suppressor cells, and neutrophils) cell populations in cancer. We also discuss the translational potential of engineered exosomes as immunomodulatory agents for cancer therapy.

Indexed as

B7-H1 AntigenB-LymphocytesDendritic CellsExosomesFas Ligand ProteinGene ExpressionHumansImmunomodulationImmunotherapyKiller Cells, NaturalMacrophagesMonocytesMyeloid-Derived Suppressor CellsNeoplasmsNeutrophilsT-LymphocytesB7-H1 AntigenCD274 protein, humanFASLG protein, humanFas Ligand Proteincancerexosomesimmunotherapylymphoid cellsmyeloid cells

Identifiers

PMID32910536
PMCPMC9116040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.